Author: PharmaSignal News Desk

Novartis Ianalumab Success marks a significant achievement in treating immune thrombocytopenia, impacting low platelet counts.

Pfizer obesity pill China deal involves a $2 billion agreement with Fosun Pharma, aiming to enhance its weight loss medication offerings.

Tecvayli multiple myeloma data presented at ASH suggests potential for early use in treatment, involving 165 patients.

Tern leukemia drug shows potential at ASH Conference, challenging Novartis’ Scemblix with promising early results.

Mirum Bluejay acquisition secures a late-stage hepatitis D drug, enhancing its pipeline with potential $200M in additional payouts.

Dyne Duchenne drug approval could challenge Sarepta’s Exondys 51, impacting the market and offering new clinical insights.

Lilly Jaypirca trial demonstrates efficacy comparable to Imbruvica with safety advantages, potentially altering leukemia and lymphoma treatment.

Vertex CRISPR therapy demonstrates early success in children with sickle cell and thalassemia, potentially expanding its market reach.

ACIP vaccine schedule is under review by a panel, following changes to the hepatitis B vaccine endorsement.

Hemophilia gene therapy faces market challenges despite innovation, with BioMarin, CSL, and Pfizer navigating barriers.